Arthur J Gallagher + Co AJG

Thesis

Arthur J Gallagher (AJG) is the world's third-largest insurance broker after Marsh McLennan and Aon. The business is fundamentally simple and beautiful: it sits between commercial buyers of insurance (mid-market companies, public entities, hospitals, contractors) and the carriers who underwrite them, collecting a commission - typically 10-15% of premium - for placing and servicing the policy. Gallagher takes no underwriting risk, holds almost no inventory, and the entire enterprise is essentially a network of producers, account executives, and a small core of analytics, claims, and benefits-consulting talent. Recurring renewal revenue (>90% client retention industrywide) plus rising rates plus tuck-in acquisitions have produced low-double-digit revenue growth for two decades.

Why it might compound: the brokerage industry is consolidating at 200-400 acquisitions per year and AJG is one of three buyers of choice. With 800+ deals completed over the last 20 years and a near-permanent runway of sub-scale brokers seeking liquidity, the reinvestment opportunity inside the circle of competence is large and durable. Float-like working capital (premiums collected and held briefly before remittance), capital-light operations (FCF/EBITDA usually 65-75% in normal years), and modest organic growth produce attractive incremental returns when leverage and integration costs are properly amortized.

The scorecard tells a more cautious story. Composite is 63 - solid but not exceptional. ROIC 10y avg printed 0.0 because amortization of acquired intangibles and the AssuredPartners deal distort GAAP returns; cash ROTCE is the relevant metric and is much higher. Net debt/EBITDA at 63.7x reflects the AssuredPartners closing in 2025 and is a one-time spike, not a steady-state. Reverse-DCF implied growth is 9.4% - reasonable given AJG's history. IV base is $295.86 versus current $208.11, so the stock trades at 0.70x base IV, with IV-low at $163.64. The price is interesting but not screamingly cheap; we want closer to $180 to underwrite a margin of safety.

Moat

AJG's moat is real but narrow rather than wide. Five lenses:

1) Pricing power. Brokerage commissions are typically a fixed percentage of premium, so AJG's revenue rises automatically with industry rate increases without any pricing action of its own - a free option on hard markets. AJG cannot, however, raise its take-rate unilaterally; commissions are negotiated against carrier appetites and client RFPs. So the pricing power is structural (commission-as-percent-of-premium) rather than discretionary. Verdict: meaningful but capped.

2) Switching costs. Mid-market commercial clients renew with their broker year after year because moving means re-marketing every line of coverage, re-underwriting employee benefits, retraining HR, and accepting potential gaps in coverage at a moment when claim history matters. Industry retention runs 90-95%. Public entity, healthcare, and benefits consulting accounts have even higher stickiness because of fiduciary, ERISA, and procurement complexity. This is the strongest moat element. Buffett's insurance commandments [1] apply to underwriters; for brokers, the analog is the agency relationship, which is even stickier because the broker is the client's agent, not the carrier's.

3) Network effects. Modest. Larger brokers attract better carrier appetites, exclusive facilities, captive arrangements, and binding authorities. Gallagher Re (reinsurance) and Gallagher Bassett (claims) both scale better than smaller competitors. But the network is not winner-take-all; Marsh, Aon, WTW, Brown & Brown all coexist. Cross-sell between P&C, benefits, and reinsurance is a genuine wedge.

4) Intangibles - brand and culture. Gallagher is an old (1927) family-founded firm with a distinctive culture ("The Gallagher Way" - 25 written tenets) that has been a real recruiting and retention asset; Pat Gallagher Jr. has been CEO since 1995. The brand carries weight with mid-market buyers and with sellers of brokerages, who prefer to sell to a permanent owner rather than to PE roll-ups that will flip the firm in five years. This intangible is durable but copyable in principle - Marsh and Aon have similar appeal.

5) Cost advantages. Limited. Brokers are people businesses; the dominant cost is producer compensation, which scales linearly with revenue. AJG has scale advantages in centralized analytics, technology, claims, and back-office (Bangalore/Kraków centers of excellence), and the larger you are the more you can afford to invest in proprietary data and AI tools. But this is a 2-3 point margin advantage over a sub-scale broker, not a GEICO-style structural wedge [2]. The Buffett canon stresses that a true low-cost moat "competitors cannot cross" [2] - AJG does not have that. It has a cost edge versus $20M-revenue regional brokers, which is precisely why the roll-up works.

Competitor stress test ($10B + 5 years). A determined entrant with $10B could buy ~$2B of revenue and become a top-10 broker, but could not become a top-3. Marsh, Aon, and AJG have decades of producer relationships, carrier facilities, and renewal books that money alone cannot replicate. PE-backed Acrisure, HUB, and Alliant have all spent more than $10B and remain second-tier. The moat against new entry is solid; the moat against the other two giants is reputational/relationship-based and any of the three could take share at the margins.

Erosion risks. AI-driven distribution disintermediating the broker (low probability in commercial mid-market, higher in personal lines and small commercial); insurtech direct-to-buyer platforms; carriers building captive distribution; commission compression as transparency increases (UK FCA already moving here). None of these are imminent, but each chips at the moat over a decade.

Moat verdict: NARROW.

Management & Capital Allocation

Pat Gallagher Jr. has been CEO since 1995 - 30 years - and Doug Howell has been CFO since 2003. This is one of the most stable management teams in financial services, and the family ownership/founder-CEO continuity produces an unusually long-term posture in a notoriously short-term industry. The capital allocation playbook has five levers; here is how AJG ranks on each:

1) Reinvestment in the existing business. Modest and effective. Gallagher Bassett (third-party claims) and Gallagher Re both have organic growth runways; investments in centers of excellence (Bangalore, Kraków, India) have meaningfully improved margins over the last decade. Producer hiring is the single biggest discretionary investment, and AJG has been disciplined about producer payback math. Grade: B+.

2) Acquisitions. This is the centerpiece. Over the last 20 years AJG has done 800+ deals at an average of $20-50M of revenue per deal, paying typically 8-12x EBITDA for tuck-ins where the cost synergies (back-office consolidation, carrier-leverage uplift, cross-sell of benefits and Gallagher Bassett) compress the post-synergy multiple to 5-7x EBITDA. This is genuine value creation. The 2024 announcement of AssuredPartners ($13.45B) is, however, by far the largest deal ever attempted and breaks the tuck-in template - it is closer to a peer acquisition. Net debt/EBITDA spiked to 63.7x in the scorer's TTM calculation [scorecard] because the deal closed mid-period and the EBITDA contribution is not yet annualized; pro-forma leverage is closer to ~4.5x and AJG has guided to deleveraging back below 3x within 24 months. Integration risk is non-trivial. Grade on the long history: A-. Grade on the AssuredPartners specific bet: incomplete - check back in 2027.

3) Debt usage. Historically prudent: investment-grade balance sheet, BBB+/Baa2, laddered maturities, and the equity issuance to partly fund AssuredPartners (a December 2024 raise of ~$5B at $284/share) shows discipline - they did not lever up to do the entire deal in debt. The 63.7x scorer figure is a transitional artifact; underwriting normal leverage at ~3-4x EBITDA puts interest coverage in the 6-8x range. Grade: B+.

4) Buybacks. Minimal and opportunistic. AJG has not been a buyback story - capital has gone to M&A and dividends. They have actually issued shares in deal currency and to fund AssuredPartners. This is acceptable when the deals create value above the dilution cost, but it removes one of the levers Buffett prizes ("buying $1 for $0.50" via repurchase). Avg P/IV when buying is therefore moot; they are not consistent buyers. Grade: B.

5) Dividends. A reliable, growing dividend - 14 consecutive years of increases at mid-single-digit growth, payout ratio ~25-30% of cash earnings. Appropriately sized for a compounder. Grade: A-.

Communication quality. Earnings calls are detailed, organic-growth disclosure is granular by segment and geography, and the CFO walks through tuck-in M&A math with rare specificity (revenue, EBITDA multiple, post-synergy multiple). The annual letter is workmanlike rather than literary; this is not Berkshire-quality candor but it is among the better disclosures in financial services. Insider ownership is meaningful (Pat Gallagher Jr. holds tens of millions of dollars of stock). Grade: A-.

Risks to the grade. AssuredPartners is the largest single bet in firm history and it changes the risk profile. If integration goes well and the deal earns its cost of capital, this is an A management team. If the deal materially misses (cultural clash, producer departures, multiple compression on the combined entity), the grade drops to B. The base rate for $13B+ services-industry deals at peer-level scale is uninspiring.

Capital allocator: B+.

Industry Structure

Insurance brokerage is a structurally attractive industry but not a moat-protected oligopoly the way credit ratings or stock exchanges are. Porter's Five Forces:

1) Rivalry among existing competitors. Moderate. The top three (Marsh McLennan, Aon, AJG) plus WTW, Brown & Brown, Lockton, HUB, Acrisure, and thousands of regional brokers compete for client renewals every year. Differentiation is real (specialty practices, geography, benefits depth, captive expertise) but commodity overlap exists at the lower mid-market. RFP win rates are roughly normal for B2B services. Importantly, rivalry does not destroy industry economics because clients value continuity and switching is costly.

2) Threat of new entrants. Low at scale, high at the bottom. Producing a new $5M-revenue boutique broker is trivial - any senior producer with a non-compete-expired book can do it. Producing a new top-10 broker requires either decades of organic build or many billions of M&A capital. The bottom-of-market entry actually feeds the roll-up: AJG buys 30-50 of these boutiques per year. So new entry is a feature, not a bug, for incumbent acquirers.

3) Bargaining power of buyers. Mixed and rising. Large corporate accounts (Marsh's stronghold) have meaningful leverage and regularly tender accounts every 3-5 years. Mid-market clients (AJG's stronghold) are far stickier and have less leverage individually, though private equity sponsors increasingly tender benefits and P&C accounts across portfolio companies. Public entity and association business has procurement-driven RFPs but extremely sticky incumbents. Net: moderate buyer power, more in large-corporate, less in mid-market.

4) Bargaining power of suppliers. The "suppliers" are insurance carriers. In hard markets carriers can squeeze brokers (smaller commissions, harder underwriting, restricted appetites); in soft markets brokers have leverage. Importantly, scale matters: AJG's volume with major carriers earns contingent commissions and supplemental revenue that smaller brokers cannot match - this is a genuine scale-driven advantage. Net: moderate, with scale tilting it toward AJG.

5) Threat of substitutes. Low to moderate. Large corporates can self-insure or use captives - already true and priced in. Direct-to-consumer carrier distribution exists in personal lines and small commercial but has not materially broken into mid-market commercial. Insurtech platforms have raised billions and produced little disruption to commercial brokerage. AI-driven underwriting may eventually compress placement effort and commissions, but the relationship/advisory layer of brokerage is hard to disintermediate. Long-tail risk over 10+ years; no immediate threat.

Value pool. Global commercial insurance premium runs ~$1.3T; brokerage commissions and fees capture roughly 8-12% of that, so the broker industry pool is ~$100-150B and growing with insured value (GDP+inflation+rate). The pool is migrating from regional brokers to top-10 firms; the top three have grown share for 20 straight years. The trajectory of the value pool is favorable for AJG.

Hard-market tailwind. Property rates have softened in 2025 [4] but casualty and specialty remain firm. Brokerage revenue is more stable than carrier revenue across cycles because commissions follow premium dollars regardless of underwriting profitability of the carrier. Buffett's commentary on softening property pricing in 2025-2026 [4] is a warning for carriers, not for brokers.

Industry Verdict: Good.

Inversion (Bear Case)

Bear case for AJG. I am the short-seller. Five sections.

1) The single event that kills this. A failed AssuredPartners integration in which 15-20% of acquired producers depart within 24 months (above the modeled 5-7%) and take their books with them. A producer with a non-compete that has expired or been negotiated around can move to Lockton, Brown & Brown, Marsh, or start a boutique with PE backing. AssuredPartners had ~10,000 employees and a producer-heavy organizational structure. AJG's tuck-in playbook works because $20-50M revenue boutiques have one or two principal producers whose retention is contractually nailed down; AssuredPartners has dozens of such producers across dozens of offices, and the cultural integration friction scales worse than linearly. If 15% of $2.4B of acquired revenue walks, AJG has paid $13.45B for an asset worth $11.5-12B and pro-forma leverage stays elevated for years longer than guided. Compounders die from one bad deal far more often than from gradual moat erosion.

2) Why the moat is narrower than bulls think. Bulls cite 90%+ retention and the Gallagher Way as proof of durable advantage. Reality: the moat is the producer's relationship with the client, not the brokerage's relationship with the client. When a senior producer leaves, the client almost always follows, regardless of the brand on the door. AJG retention is high in aggregate because most producers stay - but the structural sticking force is the producer's career-long career-economics tie to AJG (deferred comp, equity, non-compete), not customer captivity. As PE-backed competitors (HUB, Acrisure, Alliant, Hub International, Foundation Risk Partners) bid up producer compensation packages with $5-20M signing bonuses, the producer-tie weakens. The moat is rented, not owned. Brown & Brown is a useful contrast: smaller, decentralized, and arguably more producer-aligned, and has compounded faster per share than AJG over 10 years.

3) Why management is worse than it appears. Pat Gallagher Jr. is 73 years old. Succession is now a real risk - within five years the firm will be run by someone who did not build the playbook. Doug Howell is approaching retirement age too. The org has compensated by promoting from within (Patrick Gallagher III, COO; J. Patrick Gallagher, IV, others) but family-led succession in a public company can fail in either direction (entrenched mediocre heir; or external CEO who breaks the culture). More substantively: the 2024 AssuredPartners deal is a departure from the tuck-in playbook that built AJG's track record. Doing your largest-ever deal at the age of 73, with leverage going to 4-5x and equity issued at $284 (now $208 - the dilution was at a price below current), looks like late-cycle empire-building rather than disciplined capital allocation. The buyback discipline that Buffett admires - buying when the stock is cheap - is absent.

4) What bulls are extrapolating that won't hold. Bulls extrapolate the last decade's organic growth (~6-8%) and tuck-in M&A growth (~5-7%) into the next decade. Three problems. (a) The hard P&C market that boosted commissions from 2020-2024 is rolling over [4]; Buffett's 2025 letter explicitly flags property reinsurance softening and casualty inflation outpacing pricing [4], which means commission-per-policy growth slows. (b) The pool of acquirable sub-scale brokers is finite and is being drained faster than it is replenished; PE-backed roll-ups are bidding multiples up from 8-10x to 12-15x EBITDA, eroding AJG's M&A arbitrage. (c) The benefits-consulting business (a key cross-sell engine) faces AI-driven productivity compression in actuarial and analytics work, which may compress fees over a decade. None of these are catastrophic but each shaves 100-200 bps off the bull-case growth rate; cumulatively, that is the difference between a 14% IRR and an 8% IRR.

5) Valuation trap. At $208, P/E TTM is 32x [scorecard], well above the S&P average and above AJG's own decade-average of 39x only because GAAP earnings are depressed by amortization of acquired intangibles. On cash-EPS the multiple is closer to 22-24x, still a premium. Reverse-DCF implied growth is 9.4% [scorecard] - which assumes the next decade matches the last. If actual growth comes in at 6-7% (perfectly possible given the headwinds above), the fair multiple is 16-18x cash earnings, implying a stock at $140-160. The IV-low is $163.64 [scorecard]; in a recession plus a soft market plus an AssuredPartners integration miss, the stock easily revisits IV-low. The scorecard's px/IV of 0.70 sounds like upside but the IV range is wide because maintenance capex is uncertain [scorecard notes] - the wide range is honest acknowledgment that the bear scenario is live.

Multiple compression / regime change. A long-duration shift away from premium-multiple compounders (the 2022 experience) hits AJG harder than average because so much of its valuation rests on terminal-value optimism. Combined with a deal-integration miss and a soft market, the multiple-and-earnings double-compression is the trap.

If I am right, the stock could be worth $140-160 within 24-36 months - roughly 25-30% downside from $208.

Lollapalooza Bias Check

Biases active in me as the analyst right now:

Authority and social proof. Every blue-chip insurance investor (Berkshire's broker-friendliness, Markel, Lou Simpson historically) has owned or admired Gallagher, Marsh, or Aon at some point. The 'broker compounders' are a consensus quality-investor trade. I am inclined to give AJG more credit than the numbers warrant because the category is admired. The scorecard's 63 composite is a good antidote - solid, not stunning, and worth interrogating before falling into the consensus.

Anchoring to the IV base. The scorer outputs IV base = $295.86 [scorecard], and at $208 the px/IV is 0.70 - which makes the stock look meaningfully cheap. I am anchoring to $295.86 as 'truth' when the scorer notes explicitly say 'maintenance capex uncertain (>50% spread)' and 'no historical P/FCF available; using neutral 12/17/22 multiples' [scorecard notes]. The IV range is unusually wide ($163-$384) and the base case is the midpoint by construction, not by conviction. I should weight IV-low more heavily than I instinctively do, especially given the AssuredPartners overhang.

Recency and confirmation. Hard P&C market 2020-2024 boosted broker results across the board, and my recent priors lean toward 'this growth rate continues.' Buffett's 2025 letter [4] explicitly warns of property softening and casualty pricing failing to keep up with inflation - a direct contradiction of my recency bias. I should weight that more.

Commitment / consistency on the M&A roll-up thesis. I have written 'tuck-in M&A is a wonderful business model' many times before and I am inclined to extend the thesis to AssuredPartners. But AssuredPartners is not a tuck-in; it is the largest deal in firm history at peer scale, and the base rate for transformational deals in services industries is poor. I should price the deal as a discrete bet, not as more of the same.

Incentive bias - the scorecard rewards what it can measure. ROIC printed 0.0 [scorecard] because GAAP returns are distorted by acquired-intangible amortization, which the deterministic scorer cannot adjust for. I am tempted to mentally 'fix' this by quoting cash ROTCE estimates that are not in the scorer's output. That is a step toward narrative-fitting and away from numbers-honest. The right answer is to accept that the scorecard says ROIC is uncertain and to demand a wider margin of safety as compensation for the uncertainty.

Deprival super-reaction. AJG has compounded ~14% per share for 20 years. Watching it trade at 0.70x base IV makes me feel I might 'miss it.' The scorecard's recommendation framework is built precisely to prevent FOMO-driven premature buying.

Halo from the family-CEO narrative. 30-year CEO tenure is genuinely a positive but it can also become an emotional reason to overlook the AssuredPartners scale-up risk. I should separate the track record (great) from the prospective decision (pending).

10-Year Outlook

Ten-year outlook test for AJG.

Same fundamental business model in 2035? Yes with high confidence. Insurance brokerage has existed in essentially the current form for 100 years; the value of an intermediary between fragmented insureds and fragmented carriers is structural. AI may reshape parts of placement (small commercial, personal lines), but mid-market and complex commercial brokerage - AJG's bread and butter - is among the harder activities to disintermediate because it is advisory and relationship-based. Probability: ~85%.

Customer base larger? Probably yes, modestly. Global commercial insurance premium grows roughly with nominal GDP plus 1-2 points; insured value per dollar of GDP rises with cyber, climate, supply-chain, and intangible asset exposure; AJG continues to take share via M&A and producer hires. By 2035 AJG should serve materially more clients than today, with mix shifted further toward specialty, benefits, and reinsurance.

Profit per customer higher? Uncertain. Cross-sell of benefits, captive, and Gallagher Bassett raises revenue per client, but commission-rate compression (UK FCA-style transparency, AI-driven distribution, carrier direct) is a long-run pressure. Net: probably flat to slightly up.

Moat wider? Probably narrower at the margin. The AssuredPartners-scale acquirers become more numerous (PE roll-ups, larger AJG itself) and the producer-poaching war intensifies. Cultural advantage is harder to sustain at $25-30B revenue than at $8-10B. Counter: scale-driven analytics, claims, and proprietary data may build a real cost wedge over a decade.

Single biggest threat. Producer departures during the AssuredPartners integration cascading into a multi-year share loss. Second biggest: AI-driven disintermediation of small commercial and parts of mid-market over 5-10 years.

Confidence. The business will exist and be larger; the per-share earnings power and the durability of returns on capital are less certain because of the AssuredPartners bet and the late-stage nature of the M&A roll-up. The reverse-DCF implied 9.4% growth [scorecard] is achievable but not assured.

CONFIDENCE: medium